studiul factorilor critici in dizolvarea si eliberarea - Prezentare
studiul factorilor critici in dizolvarea si eliberarea - Prezentare
studiul factorilor critici in dizolvarea si eliberarea - Prezentare
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
STUDIUL FACTORILOR CRITICI IN<br />
DIZOLVAREA SI ELIBERAREA<br />
SUBSTANTELOR ACTIVE GREU<br />
SOLUBILE DIN FORMELE<br />
FARMACEUTICE<br />
Director de proiect:<br />
Dr. farm MIRCIOIU ION<br />
BIOPHARMACY & PHARMACOL RES S.A.
Denumirea <strong>si</strong> functia<br />
organizatiei<br />
participante <strong>in</strong><br />
cadrul proiectului<br />
CO -<br />
BIOPHARMACY &<br />
PHARMACOL RES<br />
S.A<br />
P1 -<br />
UNIVERSITATEA<br />
DE MEDICINA SI<br />
FARMACIE CAROL<br />
DAVILA<br />
BUCURESTI<br />
P2 –<br />
UNIVERSITATEA<br />
BUCURESTI<br />
Numele<br />
abreviat<br />
al<br />
organiza<br />
tiei<br />
Tipul<br />
organiz<br />
atiei<br />
2009 2010 2011 Total 36 luni<br />
De la<br />
bugetul de<br />
stat<br />
Credit de Credit de<br />
angajament angajament<br />
de la de la<br />
bugetul de bugetul de<br />
stat stat<br />
Cof<strong>in</strong>antare De la bugetul<br />
de stat<br />
Cof<strong>in</strong>antare De la Cof<strong>in</strong>antare<br />
bugetul de<br />
stat<br />
BIOPHA<br />
RMACY SACD 61 250 100 000 40 000 738 750 335 000 900 000 375 000<br />
UMF-<br />
CD<br />
UB<br />
UNI<br />
UNI<br />
48 750 65 000 95 245 491 005 700 000<br />
20 000 67 000 313 000 400 000<br />
Total 130 000 65 000 262 245 40 000 1 542 755 335 000 2 000 000 375 000<br />
<br />
Adresa web:<br />
http://umf.ro/<strong>in</strong>dex.php/ro/activitate-sti<strong>in</strong>tifica/cercetare
Obiectivul general al proiectului<br />
<br />
<strong>studiul</strong> fenomenelor de eliberare a substantelor active lipofile d<strong>in</strong> forme farmaceutice<br />
solide <strong>si</strong> semisolide <strong>in</strong> conditii cat mai apropiate de conditiile fiziologice <strong>si</strong> fundamentarea<br />
sti<strong>in</strong>tifica a unei standardizari a metodelor de dizolvare <strong>in</strong> vitro pentru medicamente greu<br />
solubile <strong>in</strong> ceea ce priveste utilizarea ten<strong>si</strong>oactivilor ca promotori de dizolvare<br />
Obiectivele specifice se refera la:<br />
<br />
<br />
<br />
<br />
<br />
<br />
dezvoltarea de medii biorelevante, cont<strong>in</strong>and agenti ten<strong>si</strong>oactivi fiziologici, care<br />
<strong>si</strong>muleaza cont<strong>in</strong>utul gastric/<strong>in</strong>test<strong>in</strong>al, pre- <strong>si</strong> post-prandial pentru <strong>studiul</strong> cedarii <strong>in</strong><br />
vitro a substantelor active lipofile d<strong>in</strong> forme farmaceutice solide<br />
elaborarea de medii de dizolvare alternative (agenti ten<strong>si</strong>oactivi de s<strong>in</strong>teza <strong>in</strong> concentratii<br />
apropiate celor fiziologice)<br />
elaborarea unor modele predictive <strong>in</strong> ceea ce priveste corelarea <strong>in</strong>tre metodele<br />
“fiziologice” <strong>si</strong> cele “alternative”<br />
elaborarea de strategii de dezvoltare <strong>si</strong> validare a metodelor de dizolvare <strong>in</strong> optimizarea<br />
formularii medicamentelor solide <strong>si</strong> semisolide.<br />
standardizarea <strong>si</strong> validarea unor metode pentru <strong>studiul</strong> cedarii substantelor active d<strong>in</strong><br />
forme solide <strong>si</strong> semisolide<br />
transferul metodelor catre producatorii de medicamente <strong>si</strong> catre Agentia Nationala a<br />
Medicamentului pr<strong>in</strong> <strong>in</strong>termediul colaborarii cu firmele producatoare <strong>si</strong> pr<strong>in</strong> <strong>in</strong>termediul<br />
unor cursuri <strong>si</strong> tra<strong>in</strong><strong>in</strong>guri d<strong>in</strong> univer<strong>si</strong>tatile partenere.
Elemente de orig<strong>in</strong>alitate:<br />
orig<strong>in</strong>alitatea abordarii efectelor ten<strong>si</strong>oactivilor la concentratii mult mai<br />
mici decat cele cercetate <strong>in</strong> mod uzual: concentratii apropiate de<br />
concentratia micelara critica, unde efectul acestora poate fi <strong>si</strong> el “critic”.<br />
<br />
evaluari bioanalitice cu echipamente de <strong>in</strong>alta performanta, studii, analiza<br />
biostatistica utilizand tehnici matematice avansate <strong>si</strong> softuri specializate<br />
(Topfit, PharmStat, Statistica, K<strong>in</strong>etica, SAS), analiza matematica <strong>si</strong><br />
modelare, analiza farmacoc<strong>in</strong>etica etc.<br />
Potentialii beneficiari ai acestui proiect sunt:<br />
<br />
producatorii de medicamente facilitarea studiilor de <strong>in</strong>troducere pe<br />
piata a noi produse, dar <strong>si</strong> pr<strong>in</strong> marirea predictibilitatii testelor de cedare<br />
<strong>in</strong> vitro utilizate <strong>in</strong> controlul calitatii.<br />
t<strong>in</strong>erii cercetatori formarea pentru activitatea de cercetare <strong>si</strong> cresterea<br />
competitivitatii.<br />
Proiectul este <strong>in</strong> esenta un proiect de cercetare cu aplicabilitate imediata<br />
pentru producatorii <strong>in</strong>dustriali de medicamente, dar rezultatele lui se<br />
transmit <strong>in</strong> f<strong>in</strong>al pana la patul bolnavului.
Conducatorul de proiect are 35 de ani.<br />
14 membri ai colectivului de realizare au sub 35 ani<br />
Responsabilul de proiect d<strong>in</strong> partea UMF “Carol<br />
Davila” este <strong>si</strong> conducator de doctorat.<br />
Unul d<strong>in</strong>tre doctoranzi a f<strong>in</strong>alizat <strong>si</strong> prezentat teza <strong>in</strong><br />
acest an , teza leagata esential de tematica proiectului<br />
5 doctoranzi au sust<strong>in</strong>ut teza <strong>in</strong> 2009 <strong>si</strong> trei <strong>in</strong> 2010 ,<br />
avand subiecte tangente cu tematica proiectului .<br />
Unul d<strong>in</strong>tre studentii implicati <strong>in</strong> acest proiect a<br />
realizat lucrarea de diploma <strong>in</strong> 2010 pe o tema<br />
legata de proiect.
Etapa 1 (1.10.2008 – 15.12.2008):<br />
<br />
<br />
Obiectiv: Studiul dizolvarii substantelor medicamentoase greu<br />
solubile, utilizand agenti ten<strong>si</strong>oactivi s<strong>in</strong>tetici<br />
Buget de stat: 130 000 lei<br />
Etapa 2 (15.12.2008 - 15.12.2009)<br />
<br />
<br />
Obiectiv: Solubilizarea substantelor medicamentoase <strong>in</strong> medii<br />
artificiale<br />
Buget de stat: 65 000 lei<br />
Etapa 3 (15.12.2009-10.12.2010)<br />
<br />
<br />
Obiectiv: Studiul <strong>in</strong>fluentei agentilor ten<strong>si</strong>oactivi s<strong>in</strong>tetici asupra<br />
parametrilor c<strong>in</strong>etici de cedare <strong>in</strong>-vitro d<strong>in</strong> comprimate sau forme<br />
farmaceutice semisolide (<strong>in</strong>tarzierea, panta <strong>in</strong>itiala, timpul mediu de<br />
dizolvare, gradul de dizolvare) a substantelor greu solubile.<br />
Buget de stat: 262 245 lei, cof<strong>in</strong>antare 40 000 lei
Etapa 4 (10.12.2010-1.12.2011)<br />
<br />
<br />
Obiectiv: Evaluarea c<strong>in</strong>eticii de cedare <strong>in</strong>-vitro d<strong>in</strong> forme farmaceutice<br />
solide <strong>in</strong> conditii fiziologice folos<strong>in</strong>d modele experimentale.<br />
Modelarea c<strong>in</strong>eticilor de eliberare d<strong>in</strong> forme farmaceutice solide <strong>si</strong><br />
semisolide precum <strong>si</strong> a efectelor ten<strong>si</strong>oactivilor s<strong>in</strong>tetici sau fiziologici<br />
asupra acestora. Elaborarea unor metode de cedare <strong>in</strong>-vitro<br />
de rut<strong>in</strong>a, standardizate, predictive <strong>in</strong> ceea ce priveste<br />
cedarea substantei active <strong>in</strong>-vivo, alternative la metodele<br />
utilizand ten<strong>si</strong>oactivi fiziologici.<br />
Buget de stat: 1 524 755 lei , cof<strong>in</strong>antare 335 000 lei
Activitati:<br />
3.1. Studiul solubilitatii <strong>si</strong> stabilitatii substantelor active <strong>in</strong> <strong>si</strong>steme<br />
nanostructurate <strong>si</strong>muland compozitia plasmei umane<br />
3.2. Studiul dependentei parametrilor c<strong>in</strong>etici de cedare <strong>in</strong>-vitro<br />
d<strong>in</strong> comprimate pentru substantele greu solubile, de concentratia<br />
de ten<strong>si</strong>oactivi s<strong>in</strong>tetici <strong>si</strong> de natura agentului ten<strong>si</strong>oactiv (tween,<br />
laurilsulfat de sodiu, etc) utilizat<br />
3.3. Studiul variabilitatii rezultatelor <strong>si</strong> a reprobuctibilitatii<br />
metodelor <strong>in</strong> cazul aplicarii pe comprimate d<strong>in</strong> aceea<strong>si</strong> sarja <strong>si</strong><br />
respectiv d<strong>in</strong> sarje <strong>in</strong>dustriale diferite <strong>in</strong> functie de natura <strong>si</strong><br />
concentratiile de ten<strong>si</strong>oactiv utilizate.<br />
3.4. Studiul cedarii <strong>si</strong> transportului transmembranar al<br />
substantelor active d<strong>in</strong> forme farmaceutice semisolide, utilizand<br />
diferite tipuri de membrane<br />
3.5. Disem<strong>in</strong>area rezultatelor pe scara larga, conectarea la retele de<br />
cercetare nationale <strong>si</strong> <strong>in</strong>ternationale, updatare pag<strong>in</strong>a WEB,<br />
organizare / participare la cursuri
Etapa 3-2010:<br />
Nr. Studii: 5<br />
Studiul solubilitatii Metotrexatului <strong>in</strong> surfactanti s<strong>in</strong>tetici<br />
Studiul modelarii <strong>in</strong>teractiei Metotrexat – surfactanti s<strong>in</strong>tetici<br />
Studiul reproductibilitatii <strong>si</strong> robustetii metodelor de cedare<br />
Studiul dependentei parametrilor c<strong>in</strong>etici de cedare <strong>in</strong>-vitro d<strong>in</strong><br />
comprimate pentru substantele greu solubile , de concentratia de<br />
ten<strong>si</strong>oactivi s<strong>in</strong>tetici<br />
Studiu a transferului pr<strong>in</strong> membrane semipermeabile d<strong>in</strong> forme<br />
farmaceutice semisolide, folos<strong>in</strong>d un <strong>si</strong>stem de celulele verticale<br />
de difuzie.<br />
Nr. Metode: 2<br />
Metoda de <strong>si</strong>mulare a spectrelor electronice ale medicamentelor <strong>in</strong><br />
solutii de surfactanti<br />
Metoda de modelare a corelatiei <strong>in</strong>tre proprietatile optice <strong>si</strong><br />
<strong>in</strong>teractii la nivel molecular ce <strong>in</strong>terv<strong>in</strong> <strong>in</strong>tre medicament <strong>si</strong><br />
<strong>si</strong>steme coloidale ce <strong>si</strong>muleaza plasma.
Lucrari publicate: 7<br />
Lucrari publicate <strong>in</strong> reviste cotate ISI: 3<br />
1. G Ionica, FRadulescu, D Miron, V Anuta, C Mircioiu, I Belu: Dissolution of<br />
Pentoxifyll<strong>in</strong>e from extended release formulations. Researches concern<strong>in</strong>g development of<br />
a biorelevant test, Current Health Sciences J, 35(4),286-289,2010<br />
2. I Prasacu, C Mircioiu, R Sandulovici, F Enache , Release of metoprolol from solid<br />
dosage forms. Choice and validation of theoretical model. Farmacia 57(1), 89-98, 2009<br />
3. O Purcaru, M Ionescu, C Raneti, V Anuta, I Mircioiu, I Belu Study of Nimesulide<br />
release from solid pharmaceutical formulations <strong>in</strong> Tween 80 solutions, Current Health J<br />
<br />
Vol 35 (1) 2011 –<strong>in</strong> press<br />
4. LM Miclea, L Vlaia, V Vlaia: Formulation and quality evaluation of some hydrogels<br />
conta<strong>in</strong><strong>in</strong>g piroxicam 1% and meloxicam 0.5 % , J Agroalim Proc Techn,16(1), 7-12, 2010<br />
5. D I. Hădărugăa, N G. Hădărugăb, L M Micleac, Vlaiac, C Mircioiu Bioactive<br />
compounds (hepatoprotective or anti-<strong>in</strong>flammatory xenobiotics) / cyclodextr<strong>in</strong><br />
nanoparticles: a comparative study Journal of Agroalimentary Processes and<br />
Technologies 2009, 15 (4), 478-483<br />
<br />
<br />
6. Chrenova J, Durisova M, Mircioiu C, Dedik L. Effect of gastric empty<strong>in</strong>g and enterohepatic<br />
circulation on bioequivalence assessment of ranitid<strong>in</strong>e. - Methods F<strong>in</strong>d Exp Cl<strong>in</strong><br />
Pharmacol. 2010 Jul-Aug;32(6):413-9.PMID: 20852750 [PubMed - <strong>in</strong> process]<br />
7. L - M Miclea, L Vlaia, V. Vlaia, D I. Hădărugă, C. Mircioiu Preparation and<br />
characterisation of <strong>in</strong>clu<strong>si</strong>on complexes of meloxicam and α-cyclodextr<strong>in</strong> and β-<br />
cyclodextr<strong>in</strong>. Farmacia 58 (5),583-593,2010
Brevet<br />
Mircioiu C, Cosmescu C: Gel anti<strong>in</strong>flamator ,<br />
antireumatic, anestezic, Bv 122333 B1/2009<br />
Prezentari orale: 1<br />
I Belu , O. Purcaru, M. Ionescu, C. Raneti, V. Anuta, I. Mircioiu<br />
I Belu , O. Purcaru, M. Ionescu, C. Raneti, V. Anuta, I. Mircioiu<br />
- Study Of Nimesulide Release From Solid Pharmaceutical Forms In<br />
Different Concentration Of Tween 80 - <strong>Prezentare</strong> orala <strong>in</strong> cadrul celui<br />
de-al XIV-lea Congres Naţional de Farmacie, 13-16 octombrie 2010,<br />
Targu-Mures, Romania; rezumat publicat <strong>in</strong> Acta Medica Mari<strong>si</strong>en<strong>si</strong>s<br />
(ISSN 2068-3324), Vol 56, Supplement 2, 2010, pag 88
S-au realizat obiectivele prevazute pentru acest<br />
an, chiar <strong>in</strong> conditiile unei f<strong>in</strong>antari mult<br />
reduse fata de contractul <strong>in</strong>itial.<br />
Studiile <strong>in</strong> vitro, standardizarea, validarea<br />
modelelor experimentale <strong>si</strong> teoretice, corelarile<br />
<strong>in</strong>tre metodele “fiziologice” <strong>si</strong> cele<br />
“alternative” <strong>si</strong> elaborarea unor modele<br />
predictive s-ar putea realiza <strong>in</strong> conditiile unei<br />
f<strong>in</strong>antari corespunzatoare <strong>in</strong> anul 2011, pentru<br />
a f<strong>in</strong>aliza obiectivele contractului.
Activitati:<br />
4.1. Studiul solubilizarii substantelor active, precum <strong>si</strong> al stabilitatii <strong>si</strong>stemelor<br />
rezultate <strong>in</strong> medii <strong>si</strong>muland cont<strong>in</strong>utul sucului gastric<br />
4.2. Studiul solubilizarii substantelor active, precum <strong>si</strong> al stabilitatii <strong>si</strong>stemelor<br />
rezultate <strong>in</strong> medii <strong>si</strong>muland cont<strong>in</strong>utul <strong>in</strong>test<strong>in</strong>al<br />
4.3. Studiul dependentei c<strong>in</strong>eticilor de cedare d<strong>in</strong> comprimate pentru substantele<br />
greu solubile de concentratia de acizi biliari <strong>si</strong> saruri biliare<br />
4.4. C<strong>in</strong>etici de dizolvare <strong>in</strong> volume mici de solvent, apropiate de conditiile<br />
fiziologice <strong>si</strong> estimarea c<strong>in</strong>eticii de dizolvare la volume fiziologice (100-300 ml)<br />
4.5. Studiul <strong>in</strong>fluentei unor medii <strong>si</strong>muland efectul alimentelor asupra c<strong>in</strong>eticilor<br />
de dizolvare <strong>in</strong> vitro a substantelor greu solubile d<strong>in</strong> comprimate<br />
4.6. Efectuarea de studii de cedare <strong>in</strong> vitro d<strong>in</strong> comprimate <strong>in</strong> fluide <strong>si</strong>muland<br />
mediul gastric preprandial
Activitati (cont<strong>in</strong>uare) :<br />
4.7. Efectuarea de studii de cedare <strong>in</strong> vitro d<strong>in</strong> comprimate <strong>in</strong> fluide <strong>si</strong>muland<br />
mediul <strong>in</strong>test<strong>in</strong>al preprandial<br />
4.8. Efectuarea de studii de cedare <strong>in</strong> vitro d<strong>in</strong> comprimate <strong>in</strong> fluide <strong>si</strong>muland<br />
mediul gastric postprandial<br />
4.9. Efectuarea de studii de cedare <strong>in</strong> vitro d<strong>in</strong> comprimate <strong>in</strong> fluide <strong>si</strong>muland<br />
mediul <strong>in</strong>test<strong>in</strong>al postprandial<br />
4.10. Metode factoriale <strong>in</strong> analiza <strong>factorilor</strong> <strong>critici</strong> de dizolvare<br />
4.11. Studii priv<strong>in</strong>d componenta difuzionala <strong>in</strong> cedarea d<strong>in</strong> forme farmaceutice.<br />
Solutii matematice la ecuatia difuziei <strong>in</strong> conditii <strong>in</strong>itiale <strong>si</strong> de frontiera date<br />
4.12. Analiza statistica a variabilitatii rezultatelor studiilor de cedare <strong>in</strong> vitro<br />
<br />
4.13. Studii priv<strong>in</strong>d strategii de dezvoltare <strong>si</strong> validare a metodelor de dizolvare <strong>in</strong><br />
optimizarea formularii medicamentelor solide <strong>si</strong> semisolide<br />
4.14. Standardizare metode de <strong>studiul</strong> cedarii d<strong>in</strong> forme farmaceutice semisolide<br />
4.15. Elaborarea unor metrici de comparare a curbelor de dizolvare obt<strong>in</strong>ute <strong>in</strong><br />
conditii diferite<br />
4.16. Corelari <strong>in</strong>tre metodele “fiziologice” <strong>si</strong> cele “alternative” <strong>si</strong> elaborarea unor<br />
modele predictive<br />
4.17. Estimarea gradului de predictibilitate asupra comportamentului <strong>in</strong>-vivo<br />
pentru modelele elaborate<br />
4.18. Analiza beneficiu/risc <strong>in</strong> cazul folo<strong>si</strong>rii metodelor alternative <strong>in</strong> locul celor<br />
cu reactivi fiziologici<br />
4.19. Disem<strong>in</strong>are rezultate: conectarea la retele de cercetare nationale <strong>si</strong><br />
<strong>in</strong>ternationale, updatare pag<strong>in</strong>a WEB, organizare / participare la cursuri.<br />
Identificare <strong>si</strong> atribuirea drepturilor de proprietate <strong>in</strong>telectuala
Activitatile pentru 2011 , <strong>in</strong> numar de 19 sunt<br />
realizabile <strong>in</strong> conditiile f<strong>in</strong>antarii complete<br />
(<strong>in</strong>clu<strong>si</strong>v fondurile transferate pentru activitati<br />
reportate).<br />
S-ar putea reduce cheltuielile cu circa 20 - 25%<br />
S-ar putea reduce cheltuielile cu circa 20 - 25%<br />
pr<strong>in</strong> reducerea numarului de determ<strong>in</strong>ari . In<br />
aceste conditii activitatile de validare <strong>si</strong><br />
standardizare ( 4.13 – 4.18 ) vor fi mai put<strong>in</strong><br />
semnificative statistic.